TandemAI
腾迈医药
TandemAI (腾迈医药) is an AI-driven drug discovery company that pairs large-model AI with physics-based computational tools to reshape the drug discovery process — in CEO and co-founder Qi He's (何骑) words, "to reshape the new landscape of drug discovery by improving access to world-leading AI and physics-based computational tools" . It's a Qiming Venture Partners portfolio company, named by Qiming alongside Meirui Chemical as one of its two key CRO bets in AI chemistry . In mid-2025 it completed a merger with peptide-focused Dongtai Pharmaceuticals (动肽医药) , and in November 2025 it announced a $22 million Series A extension to scale its drug discovery platform, with Qiming continuing to invest . As of Qiming's May 2026 reporting, it was also among the firm's portfolio companies named to VBData's 2026 Future Healthcare 100 .
AI-generated — may contain errors, please verify.
Coverage
Qiming Venture Partners and Nearly 40 Portfolio Companies Named to VBData 2026 Future Healthcare 100
China's most authoritative and influential innovation benchmark for the healthcare industry
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 40, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners Weekly | Portfolio Companies Funding and Updates Vol. 29, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies.
Qiming Venture Partners Portfolio Companies Shine at 2025 World Artificial Intelligence Conference
As one of the most influential industry events in the global artificial intelligence sector, the 2025 World Artificial Intelligence Conference took "Intelligent Era: Shared Responsibility for Our Planet" as its theme, continuing to serve its important roles as a "technology weathervane, application showcase, industry accelerator, and governance forum" — comprehensively presenting the latest developments in cutting-edge AI technology, industrial trends, and global governance practices.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 25, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners Portfolio Companies Shine on 2025 China Globalization Rising Stars 100 List
The ranking focuses on companies that achieved at least $10 million in overseas revenue in 2024, as well as companies that have already generated overseas revenue to date and possess strategic deployment capabilities in the global market.
Qiming Venture Partners' Kan Chen: AI's Transformation of Biomedicine Is Already Evident
In the AI era, drug discovery is taking on the characteristics of data-driven, high-throughput, automated, and intelligent processes, potentially improving success rates and lowering costs. In the near term, the necessity of experimental validation will remain unchanged; over the long run, the foundational theories of biology will stay stable. This balance between transformation and continuity is reshaping the entire landscape of pharmaceutical R&D.
